Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a rice protein help you sleep better?

NCT ID NCT07258433

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial tested PeptiSleep, a plant-based supplement made from rice protein, to see if it improves sleep quality in healthy adults. 120 participants took either PeptiSleep or a placebo daily for 6 weeks while wearing a sleep tracker and completing surveys. The study measured changes in sleep quality using standard questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PeptiSleep (rice protein hydrolysate)
What this could lead to
If it works, this could point toward a natural, plant-based supplement to help healthy adults sleep better.
What could go wrong
This is a small, completed trial with only 120 healthy adults. Results may not apply to people with sleep disorders, and the supplement may not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Dec 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 at the time of enrollment. * Generally healthy * BMI 18.5 - 35.0kg/m2 * Willing and able to provide informed consent. * Willing to consume one PeptiSleep or placebo capsule daily for 6 weeks. * Willing to wear a sleep tracker continuously throughout the study period. * Willing to complete all scheduled surveys and cognitive assessments on Days 0, 1, 2, and 3, at biweekly check-ins (Week 2 and Week 4), and at End-of-Study (Day 42). * Willing to sync their wearable device data through the Reputable Health app and complete daily check-ins for compliance assessment * Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period. * Agree to maintain a stable lifestyle and medication routines for at least 4 weeks prior to enrollment * Agree not to use other medicines or supplements for sleep, stress, depression, or anxiety other than the test product during enrolment period. * Agree to refrain from participation in another clinical trial during enrolment period. * Agree to comply with Creyos digital platform data usage and privacy policy Exclusion Criteria: * Are currently pregnant, breastfeeding, or planning pregnancy during the study period. * Are using prescription or over-the-counter sleep medications (e.g., zolpidem, melatonin \>5 mg, benzodiazepines, CBD or antihistamines used for sleep, stress, depression, or anxiety within 4-weeks prior to enrolment. * Have a current diagnosis of a chronic medical condition or illness (e.g., uncontrolled thyroid disease, diabetes, cardiovascular disease, major depressive disorder, or anxiety disorder requiring ongoing pharmacologic treatment) or a chronic sleep disorder, insomnia, restless leg syndrome, sleep apnoea. * Are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 4-weeks and any other sleep clinical trial during the past 3 months. * Have a known allergy or sensitivity to any component of the investigational or placebo product * Are shift workers or have highly irregular sleep/wake schedules that could confound study outcomes. * Are unable or unwilling to comply with daily product use, wearable requirements, or survey/assessment completion. * Have with significant non-wear time of their Oura device exceeding a 48- hour period * Are using medications which induce CYP3A4 such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids. * Are using prescription or OTC medications or supplements for sleep, stress, depression, or anxiety including CBD within one month prior to enrolment. * Are using aromatherapy to help manage sleep, stress, depression, or anxiety within 4-weeks prior to enrolment. * Are using a digital device (besides Oura) to help monitor or manage sleep during the study period. * Have a current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years. * Have been diagnosed with or have consistent gastrointestinal issues that disrupt sleep. * Have a history of renal function impairment * Have with COPD or a chronic breathing disorder * Are active smokers, nicotine use or drug (prescription or illegal substances) abuse. * Have a chronic past and/or current alcohol use (\>14 alcoholic drinks week) * Are regularly taking stimulants (e.g., coffee, caffeine supplements, beverages containing caffeine) 5 hours before bed * Are regularly consuming more than 500mg of caffeine per day * Have any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive abilities are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Reputable Labs Inc.

    Wilmington, Delaware, 19808, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.